Titre : Sphingolipides

Sphingolipides : Questions médicales fréquentes

Termes MeSH sélectionnés :

Pilot Projects
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Sphingolipides : Questions médicales les plus fréquentes", "headline": "Sphingolipides : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Sphingolipides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-13", "dateModified": "2025-03-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Sphingolipides" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Lipides membranaires", "url": "https://questionsmedicales.fr/mesh/D008563", "about": { "@type": "MedicalCondition", "name": "Lipides membranaires", "code": { "@type": "MedicalCode", "code": "D008563", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Glycosphingolipides", "alternateName": "Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D006028", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides", "code": { "@type": "MedicalCode", "code": "D006028", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Glycosphingolipides acides", "alternateName": "Acidic Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D020384", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides acides", "code": { "@type": "MedicalCode", "code": "D020384", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gangliosides", "alternateName": "Gangliosides", "url": "https://questionsmedicales.fr/mesh/D005732", "about": { "@type": "MedicalCondition", "name": "Gangliosides", "code": { "@type": "MedicalCode", "code": "D005732", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } }, { "@type": "MedicalWebPage", "name": "Sulfoglycosphingolipides", "alternateName": "Sulfoglycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D013433", "about": { "@type": "MedicalCondition", "name": "Sulfoglycosphingolipides", "code": { "@type": "MedicalCode", "code": "D013433", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.837" } } } ] }, { "@type": "MedicalWebPage", "name": "Gangliosides", "alternateName": "Gangliosides", "url": "https://questionsmedicales.fr/mesh/D005732", "about": { "@type": "MedicalCondition", "name": "Gangliosides", "code": { "@type": "MedicalCode", "code": "D005732", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } }, { "@type": "MedicalWebPage", "name": "Sulfoglycosphingolipides", "alternateName": "Sulfoglycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D013433", "about": { "@type": "MedicalCondition", "name": "Sulfoglycosphingolipides", "code": { "@type": "MedicalCode", "code": "D013433", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.837" } } }, { "@type": "MedicalWebPage", "name": "Glycosphingolipides neutres", "alternateName": "Neutral Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D020383", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides neutres", "code": { "@type": "MedicalCode", "code": "D020383", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Céramides", "alternateName": "Ceramides", "url": "https://questionsmedicales.fr/mesh/D002518", "about": { "@type": "MedicalCondition", "name": "Céramides", "code": { "@type": "MedicalCode", "code": "D002518", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } } ] }, { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } }, { "@type": "MedicalWebPage", "name": "Sphingomyéline", "alternateName": "Sphingomyelins", "url": "https://questionsmedicales.fr/mesh/D013109", "about": { "@type": "MedicalCondition", "name": "Sphingomyéline", "code": { "@type": "MedicalCode", "code": "D013109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.870" } } } ] }, { "@type": "MedicalWebPage", "name": "Céramides", "alternateName": "Ceramides", "url": "https://questionsmedicales.fr/mesh/D002518", "about": { "@type": "MedicalCondition", "name": "Céramides", "code": { "@type": "MedicalCode", "code": "D002518", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } } ] }, { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } }, { "@type": "MedicalWebPage", "name": "Sphingomyéline", "alternateName": "Sphingomyelins", "url": "https://questionsmedicales.fr/mesh/D013109", "about": { "@type": "MedicalCondition", "name": "Sphingomyéline", "code": { "@type": "MedicalCode", "code": "D013109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.870" } } }, { "@type": "MedicalWebPage", "name": "Psychosine", "alternateName": "Psychosine", "url": "https://questionsmedicales.fr/mesh/D011609", "about": { "@type": "MedicalCondition", "name": "Psychosine", "code": { "@type": "MedicalCode", "code": "D011609", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.806" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Sphingolipides", "alternateName": "Sphingolipids", "code": { "@type": "MedicalCode", "code": "D013107", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Erich Gulbins", "url": "https://questionsmedicales.fr/author/Erich%20Gulbins", "affiliation": { "@type": "Organization", "name": "Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany." } }, { "@type": "Person", "name": "Giovanni D'Angelo", "url": "https://questionsmedicales.fr/author/Giovanni%20D%27Angelo", "affiliation": { "@type": "Organization", "name": "Interfaculty Institute of Bioengineering, Ecole polytechnique fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland giovanni.dangelo@epfl.ch Christopher.Clarke@stonybrookmedicine.edu lianacsilva@ff.ulisboa.pt." } }, { "@type": "Person", "name": "Anna Kovilakath", "url": "https://questionsmedicales.fr/author/Anna%20Kovilakath", "affiliation": { "@type": "Organization", "name": "Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States." } }, { "@type": "Person", "name": "L Ashley Cowart", "url": "https://questionsmedicales.fr/author/L%20Ashley%20Cowart", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States." } }, { "@type": "Person", "name": "Tyrone Dowdy", "url": "https://questionsmedicales.fr/author/Tyrone%20Dowdy", "affiliation": { "@type": "Organization", "name": "Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Service development project to pilot a digital technology innovation for video direct observation of therapy in adult patients with asthma.", "datePublished": "2024-07-15", "url": "https://questionsmedicales.fr/article/39009461", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjoq-2023-002626" } }, { "@type": "ScholarlyArticle", "name": "Mind the gap: analysis of two pilot projects of a home telehealth service for persons with complex conditions in a Swedish hospital.", "datePublished": "2023-05-09", "url": "https://questionsmedicales.fr/article/37161458", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12913-023-09409-4" } }, { "@type": "ScholarlyArticle", "name": "A pilot project to explore the mental health and wellbeing among cardiothoracic staff and the impact of virtual reality guided mindfulness.", "datePublished": "2024-10-01", "url": "https://questionsmedicales.fr/article/39354593", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13019-024-03089-9" } }, { "@type": "ScholarlyArticle", "name": "Contextualizing Inequities in COVID Vaccination Trends Among Project REFOCUS Pilot Sites: Racism-Related Determinants of Health.", "datePublished": "2024-05-27", "url": "https://questionsmedicales.fr/article/38854790", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18865/ed.34.1.1" } }, { "@type": "ScholarlyArticle", "name": "Assessing the carbon emission performance of digital greening synergistic transformation: evidence from the dual pilot projects in China.", "datePublished": "2023-10-18", "url": "https://questionsmedicales.fr/article/37853219", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11356-023-30270-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Lipides", "item": "https://questionsmedicales.fr/mesh/D008055" }, { "@type": "ListItem", "position": 3, "name": "Lipides membranaires", "item": "https://questionsmedicales.fr/mesh/D008563" }, { "@type": "ListItem", "position": 4, "name": "Sphingolipides", "item": "https://questionsmedicales.fr/mesh/D013107" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Sphingolipides - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Sphingolipides", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Sphingolipides", "description": "Comment diagnostiquer une maladie liée aux sphingolipides ?\nQuels tests sont utilisés pour évaluer les sphingolipides ?\nLes symptômes peuvent-ils indiquer un déséquilibre des sphingolipides ?\nQuelle imagerie est utile pour les maladies des sphingolipides ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Sphingolipides", "description": "Quels sont les symptômes des troubles liés aux sphingolipides ?\nLes troubles digestifs sont-ils associés aux sphingolipides ?\nComment les sphingolipides affectent-ils le système nerveux ?\nLes troubles de la peau sont-ils fréquents avec les sphingolipides ?\nLes symptômes varient-ils selon le type de sphingolipide ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Sphingolipides", "description": "Peut-on prévenir les maladies liées aux sphingolipides ?\nLes tests génétiques aident-ils à la prévention ?\nL'éducation sur les sphingolipides est-elle importante ?\nLes habitudes alimentaires influencent-elles la santé des sphingolipides ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Sphingolipides", "description": "Quels traitements existent pour les maladies des sphingolipides ?\nLa diète peut-elle influencer les niveaux de sphingolipides ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements expérimentaux pour ces maladies ?\nLa thérapie génique est-elle une option pour ces maladies ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Sphingolipides", "description": "Quelles complications peuvent survenir avec les troubles des sphingolipides ?\nLes troubles respiratoires sont-ils une complication possible ?\nComment les sphingolipides affectent-ils le cœur ?\nLes complications neurologiques sont-elles fréquentes ?\nLes complications peuvent-elles être réversibles ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Sphingolipides", "description": "Quels sont les facteurs de risque pour les maladies des sphingolipides ?\nL'âge influence-t-il le risque de troubles des sphingolipides ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes infections peuvent-elles aggraver les troubles des sphingolipides ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Pilot+Projects&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une maladie liée aux sphingolipides ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les sphingolipides ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses d'urine mesurent les niveaux de sphingolipides." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils indiquer un déséquilibre des sphingolipides ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes neurologiques ou cutanés peuvent signaler un déséquilibre." } }, { "@type": "Question", "name": "Quelle imagerie est utile pour les maladies des sphingolipides ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM et la TDM peuvent aider à visualiser les effets des maladies sur les organes." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents familiaux peuvent indiquer une prédisposition génétique aux maladies." } }, { "@type": "Question", "name": "Quels sont les symptômes des troubles liés aux sphingolipides ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des problèmes cutanés et des douleurs." } }, { "@type": "Question", "name": "Les troubles digestifs sont-ils associés aux sphingolipides ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles digestifs peuvent être liés à des anomalies des sphingolipides." } }, { "@type": "Question", "name": "Comment les sphingolipides affectent-ils le système nerveux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils jouent un rôle dans la myélinisation et la signalisation neuronale, affectant la fonction nerveuse." } }, { "@type": "Question", "name": "Les troubles de la peau sont-ils fréquents avec les sphingolipides ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des affections cutanées comme l'eczéma peuvent être liées à des déséquilibres." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de sphingolipide ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de sphingolipide impliqué et de l'organe affecté." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux sphingolipides ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les tests génétiques aident-ils à la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les personnes à risque et guider la prévention." } }, { "@type": "Question", "name": "L'éducation sur les sphingolipides est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre les sphingolipides aide à reconnaître les symptômes et à agir rapidement." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles la santé des sphingolipides ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut soutenir la santé des sphingolipides et prévenir des troubles." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider à prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les troubles liés aux sphingolipides." } }, { "@type": "Question", "name": "Quels traitements existent pour les maladies des sphingolipides ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies enzymatiques, des médicaments et des soins symptomatiques." } }, { "@type": "Question", "name": "La diète peut-elle influencer les niveaux de sphingolipides ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides gras essentiels peut aider à réguler les sphingolipides." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils réduire les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent atténuer les symptômes et améliorer la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour ces maladies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques explorent de nouvelles thérapies pour les troubles des sphingolipides." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option pour ces maladies ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche pour traiter certaines maladies liées aux sphingolipides." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les troubles des sphingolipides ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques graves, des infections et des défaillances organiques." } }, { "@type": "Question", "name": "Les troubles respiratoires sont-ils une complication possible ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles des sphingolipides peuvent entraîner des complications respiratoires." } }, { "@type": "Question", "name": "Comment les sphingolipides affectent-ils le cœur ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des déséquilibres peuvent contribuer à des maladies cardiovasculaires et à des arythmies." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications comme la démence ou des troubles moteurs peuvent survenir." } }, { "@type": "Question", "name": "Les complications peuvent-elles être réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les maladies des sphingolipides ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des déséquilibres nutritionnels." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de troubles des sphingolipides ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles apparaissent plus fréquemment chez les enfants ou les personnes âgées." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de troubles liés aux sphingolipides." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver les troubles des sphingolipides ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent exacerber les symptômes et les complications." } } ] } ] }

Sous-catégories

17 au total
└─

Glycosphingolipides

Glycosphingolipids D006028 - D10.570.877.360
└─└─

Glycosphingolipides acides

Acidic Glycosphingolipids D020384 - D10.570.877.360.025
└─└─

Glycosphingolipides neutres

Neutral Glycosphingolipids D020383 - D10.570.877.360.612
└─└─

Psychosine

Psychosine D011609 - D10.570.877.360.806
└─└─└─

Gangliosides

Gangliosides D005732 - D10.570.877.360.025.475
└─└─└─

Sulfoglycosphingolipides

Sulfoglycosphingolipids D013433 - D10.570.877.360.025.837
└─└─└─

Céramides

Ceramides D002518 - D10.570.877.360.612.200
└─└─└─

Sphingomyéline

Sphingomyelins D013109 - D10.570.877.360.612.870
└─└─└─└─

Ganglioside GM1

G(M1) Ganglioside D005677 - D10.570.877.360.025.475.390
└─└─└─└─

Ganglioside GM2

G(M2) Ganglioside D005678 - D10.570.877.360.025.475.400
└─└─└─└─

Ganglioside GM3

G(M3) Ganglioside D005679 - D10.570.877.360.025.475.510
└─└─└─└─

Cérébrosides

Cerebrosides D002554 - D10.570.877.360.612.200.250
└─└─└─└─

Globosides

Globosides D005915 - D10.570.877.360.612.200.425
└─└─└─└─

Lactosylcéramides

Lactosylceramides D007790 - D10.570.877.360.612.200.612
└─└─└─└─

Trihexosylcéramide

Trihexosylceramides D014281 - D10.570.877.360.612.200.906
└─└─└─└─└─

Galactosylcéramides

Galactosylceramides D005699 - D10.570.877.360.612.200.250.450
└─└─└─└─└─

Glucosylcéramides

Glucosylceramides D005963 - D10.570.877.360.612.200.250.490

Sources (10000 au total)

Service development project to pilot a digital technology innovation for video direct observation of therapy in adult patients with asthma.

Adherence to pharmacotherapy and use of the correct inhaler technique are important basic principles of asthma management. Video- or remote-direct observation of therapy (v-DOT) could be a feasible ap... To explore the utility and the feasibility of v-DOT to monitor inhaler technique and adherence to treatment in adults attending the asthma outpatient service in a tertiary hospital in Northern Ireland... The project evaluated use of the technology with 10 asthma patients. Patient and clinician feedback was obtained, in addition to measures of patient engagement and disease-specific clinical markers to... The engagement rate with v-DOT for participating patients averaged 78% (actual video uploads vs expected video uploads) over a median 7 week usage period. Although 50% of patients reported a technical... The v-DOT technology was shown to be a feasible method of assessing inhaler technique and monitoring adherence in this small group of adult asthma patients. A range of positive impacts for participati...

Mind the gap: analysis of two pilot projects of a home telehealth service for persons with complex conditions in a Swedish hospital.

Developing and implementing home telehealth (HTH) services for patients with chronic conditions is a challenge. HTH services provide continuous and integrated care to patients, but very often pilot pr... To plan and evaluate the service for the recipients (i.e., patients and healthcare providers), we used the Plan-Do-Study-Act (PDSA) tool in combination with two complexity-informed frameworks: the Non... Patients and staff perceived the services as valuable as they enabled rapid feedback, and improved communication and collaboration between patients and healthcare providers. Yet, despite the extensive... The combined use of PDSA, NASSS, and CAT can support the development and evaluation of HTH services that are perceived as valuable by individual patients and staff. For successful adoption, the value ...

A pilot project to explore the mental health and wellbeing among cardiothoracic staff and the impact of virtual reality guided mindfulness.

The Cardio-Thoracic (CT) professional group experienced a significant increase in stress and workload during and after the COVID-19 pandemic. The Society for Cardiothoracic Surgery (SCTS) in Great Bri... In February 2022, the SCTS created a Mental Health and Wellbeing Working Group to identify the problem and find solutions. This exploratory project was carried out in two stages. Stage one was an onli... Stage one: An online QR code survey was sent out to 150 members with 129 (86%) completed responses. 92% expressed that SCTS should create awareness about mental health and wellbeing. 99% said that the... Our study findings indicate that CT staff experience considerable effects on their mental health and wellbeing. However, there is a hesitancy to recognise and seek assistance due to concerns about con...

Contextualizing Inequities in COVID Vaccination Trends Among Project REFOCUS Pilot Sites: Racism-Related Determinants of Health.

Coronavirus disease (COVID) dashboards rarely provide insights about the racialized contexts in which vaccination inequities occur.... The purpose of this study was to use the emerging Project REFOCUS dashboard to contextualize COVID vaccination patterns among 6 diverse communities.... We queried the dashboard to generate descriptive statistics on vaccination trends and racism-related contextual factors among the 6 Project REFOCUS pilot sites (Albany, Georgia, Bronx, New York, Detro... Vaccination rates, demographic indicators, and contextual factors differed across sites. As of October 17, 2022, the proportion of people who had received at least 1 COVID vaccine dose ranged from 58.... The dashboard integrates racism-related factors with COVID vaccination visualizations and provides a fuller picture of the context in which COVID trends are occurring.... Community organizers, researchers, policymakers, and practitioners can track racism-related factors and other social determinants of health as part of the contexts in which COVID-related inequities oc...

Improving pediatric atopic dermatitis care in the emergency department and primary care setting: a collaborative quality improvement pilot project.

Emergency department visits and healthcare expenditures for pediatric atopic dermatitis have been increasing over the last two decades. There is a paucity of replicable quality improvement initiatives...

Text Message Reminders to Improve Immunization Appointment Attendance in Alberta, Canada: The Childhood Immunization Reminder Project Pilot Study.

Vaccine coverage for 18-month-old children in Canada is often below the recommended level, which may be partially because of parental forgetfulness. SMS text message reminders have been shown to poten... This study aimed to assess the effectiveness and acceptability of using SMS text messages containing a link to web-based immunization information in different languages to remind parents of their chil... The Childhood Immunization Reminder Project was a pilot intervention at 2 public health centers, one each in Lethbridge and Edmonton, Alberta, Canada. Two SMS text message reminders were sent to paren... Following the intervention, the health center in Edmonton had a reduction of 6.4% (95% CI 3%-9.8%) in appointment no-shows, with no change at the Lethbridge Health Center (0.8%, 95% CI -1.4% to 3%). T... The study's findings support the use of SMS text message reminders as a convenient and acceptable method to minimize parental forgetfulness and potentially reduce appointment no-shows. The diverse lan...

Enhancing the capacity of community health workers in prevention and control of epidemics and pandemics in Wakiso district, Uganda: evaluation of a pilot project.

Community Health Workers (CHWs) play a crucial role in outbreak response, including health education, contact tracing, and referral of cases if adequately trained. A pilot project recently trained 766... This was a qualitative evaluation carried out one year after the project. It used three data collection methods: 30 in-depth interviews among trained CHWs; 15 focus group discussions among community m... Findings from the study are presented under four themes. (1) Improved knowledge and skills on managing epidemics and pandemics. CHWs distinguished between the two terminologies and correctly identifie... These findings demonstrate that CHWs can support epidemic and pandemic response when their capacity is enhanced. There is need to invest in routine training of CHWs to contribute to outbreak preparedn...

Pilot study of a manualised mental health awareness and stigma reduction intervention for Black faith communities in the UK: ON TRAC project.

Building partnerships between mental health services and Black faith communities to co-produce culturally tailored interventions is an essential step towards improving access to services and reducing ... This study employed a mixed methods pre-post-design, based upon the Medical Research Council Framework (MRC) for complex interventions, and the Implementation Science Research Development.... The qualitative assessments indicate that the intervention was found overall to be acceptable and feasible to the Black faith community population. This pilot study did not find statistically signific... This ON TRAC pilot study shows that the intervention was feasible and acceptable, and that it has promising positive impacts and next requires larger scale evaluation. These results demonstrate that t... ISRCTN12253092....